Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

0.4837
-0.0334-6.46%
Pre-market: 0.52040.0367+7.59%07:05 EDT
Volume:1.26M
Turnover:630.26K
Market Cap:142.80M
PE:-0.37
High:0.5530
Open:0.5101
Low:0.4810
Close:0.5171
Loading ...

Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges

TIPRANKS
·
13 Mar

Lyell Immunopharma Q4 Sales $11.00K Down From $13.00K YoY

Benzinga
·
12 Mar

BRIEF-Lyell Immunopharma Q4 Net Income USD -191.935 Million

Reuters
·
12 Mar

Lyell Immunopharma Q4 Revenue USD 11 Thousand

THOMSON REUTERS
·
12 Mar

Lyell Immunopharma Q4 Operating Expenses USD 201.158 Million

THOMSON REUTERS
·
12 Mar

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
19 Feb

Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners

Simply Wall St.
·
17 Feb

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake

Simply Wall St.
·
31 Jan

Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why

Zacks
·
23 Jan

Lyell Immunopharma price target lowered to 60c from $1 at BofA

TIPRANKS
·
12 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)

TIPRANKS
·
11 Jan

After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Zacks
·
30 Dec 2024

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
24 Dec 2024

Lyell Immunopharma presents positive data from Phase 1-2 IMPT-314 study

TIPRANKS
·
10 Dec 2024

BRIEF-Lyell Immunopharma Says Impt-314 Receives Fast Track Designation From FDA

Reuters
·
10 Dec 2024